Status:
NOT_YET_RECRUITING
Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan
Lead Sponsor:
RESnTEC, Institute of Research
Conditions:
Proteinuria
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Losartan, an angiotensin II receptor blocker, has already been established as a treatment for diabetic nephropathy due to its ability to reduce blood pressure and mitigate the progression of kidney da...
Eligibility Criteria
Inclusion
- Patients of both genders with ≥18 years of age.
- Presence of proteinuria/albuminuria at time of screening.
- Creatinine clearance of 30 mL/min or higher.
Exclusion
- A systolic blood pressure of 180 mm Hg or higher, a diastolic blood pressure of 110 mm Hg or higher.
- Presence of a second primary renal disease in addition to diabetic nephropathy.
- Patients with type 1 diabetes.
- A history of a cardiovascular or cerebrovascular event within 3 months before inclusion.
- Serum potassium of 6.0 mmol/L or higher.
- Transplantation or immunosuppressive treatment.
- Contraindication for the use of losartan or hydrochlorothiazide.
- Pregnancy or lactation.
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2025
Estimated Enrollment :
234 Patients enrolled
Trial Details
Trial ID
NCT06491940
Start Date
August 1 2024
End Date
July 31 2025
Last Update
July 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical department, Bahawal Victoria Hospital
Bahawalpur, Punjab Province, Pakistan, 06318